Aulos Bioscience to Present Promising Phase 2 Data for AU-007 at 39th SITC Annual Meeting

Aulos Bioscience, an innovative company in immuno-oncology, has shared encouraging safety and efficacy results from Phase 2 dose expansion cohorts in their ongoing Phase 1/2 clinical trial of AU-007. This trial focuses on patients with unresectable locally advanced or metastatic solid tumors. These findings are set to be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, which will be held both virtually and in Houston, Texas, from November 6-10, 2024.

Aron Knickerbocker, the president and CEO of Aulos Bioscience, expressed enthusiasm about the Phase 2 dose expansion data for their monoclonal antibody AU-007. Building on the positive clinical results previously presented at the American Society of Clinical Oncology (ASCO), Aulos Bioscience looks forward to sharing further details, particularly early Phase 2 data in melanoma and renal cell carcinoma, at the upcoming SITC Annual Meeting.

The poster presentation will be available on Friday, November 8, 2024, from 9:00 a.m. to 7:00 p.m. CST in Exhibit Halls AB at the George R. Brown Convention Center. An electronic version will also be accessible via the SITC 2024 virtual meeting platform.

AU-007 is a human IgG1 monoclonal antibody designed computationally to target the CD25-binding portion of interleukin-2 (IL-2). Its unique mechanism of action involves leveraging IL-2 to enhance anti-tumor immune responses. AU-007 works by preventing IL-2 from binding to trimeric receptors on regulatory T cells, while still allowing IL-2 to interact with and expand effector T cells and natural killer (NK) cells. This approach mitigates the negative feedback loop seen in other IL-2-based treatments, thus promoting immune system activation rather than suppression. Additionally, AU-007 prevents IL-2 from binding to CD25-containing receptors on eosinophils and vascular and pulmonary endothelium, potentially reducing vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

Aulos Bioscience is committed to advancing cancer treatment by developing superior IL-2 therapeutics that harness the body's immune system to target and destroy cancer cells. The company's initial clinical candidate, AU-007, exemplifies their approach by utilizing advanced machine learning from their co-founder Biolojic Design and an extensive understanding of immunology. This groundbreaking human antibody aims to enhance tumor-killing capabilities while minimizing the immunosuppression and toxic side effects typically seen with IL-2 therapies.

Founded by Biolojic Design and Apple Tree Partners (ATP), Aulos Bioscience is led by experts in artificial intelligence, antibody development, and cancer immunotherapies. The company’s innovative strategies and pioneering leadership underscore their mission to revolutionize cancer care through cutting-edge immuno-oncology solutions.